Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Trazodone and valproate in patients discontinuing long-term benzodiazepinetherapy: effects on withdrawal symptoms and taper outcome
Autore:
Rickels, K; Schweizer, E; Espana, FG; Case, G; DeMartinis, N; Greenblatt, D;
Indirizzi:
Univ9104n, Dept Psychiat, Mood & Anxiety Disorders Sect, Philadelphia, PA 1 Univ Penn Philadelphia PA USA 19104 ty Disorders Sect, Philadelphia, PA 1 Sch Med, Div Clin Pharmacol, Boston, MA USA Sch Med Boston MA USASch Med, Div Clin Pharmacol, Boston, MA USA New England Med Ctr, Boston, MA 02111 USA New England Med Ctr Boston MA USA 02111 and Med Ctr, Boston, MA 02111 USA
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 1, volume: 141, anno: 1999,
pagine: 1 - 5
Fonte:
ISI
Lingua:
ENG
Soggetto:
RAT-BRAIN; METABOLITE; LORAZEPAM; BUSPIRONE; DIAZEPAM; SEVERITY; PLACEBO; ACID;
Keywords:
substance withdrawal syndrome; benzodiazepine anxiolytics; anxiety disorders; trazodone; valproate; benzodiazepine discontinuation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Rickels, K UnivMktnn, Dept Psychiat, Mood & Anxiety Disorders Sect, Univ Sci Ctr,3600 Univ Penn Univ Sci Ctr,3600 Mkt St,Suite 803 Philadelphia PA USA 19104
Citazione:
K. Rickels et al., "Trazodone and valproate in patients discontinuing long-term benzodiazepinetherapy: effects on withdrawal symptoms and taper outcome", PSYCHOPHAR, 141(1), 1999, pp. 1-5

Abstract

Recent uncontrolled research suggested that trazodone and sodium valproatemay be helpful in benzodiazepine (BZ) discontinuation. We therefore undertook a double-blind study to assess whether trazodone and valproate, as compared to placebo, would attenuate withdrawal and facilitate discontinuation in BZ-dependent patients with a minimum of 1 year daily BZ use. Seventy-eight patients, taking a mean dose of 19 +/- 17 mg/day of diazepam (or its equivalent), were stabilized for several weeks on their BZ (16 diazepam, 25 lorazepam, 37 alprazolam) and then for 1-2 weeks, pretreated with trazodone, sodium valproate or placebo before being tapered at 25% per week. All treatments were continued for 5 weeks post-taper. BZ-free status was assessed after 5 and 12 weeks post-taper. Neither trazodone nor valproate had any significant effect on withdrawal severity. Peak physician withdrawal checklist change from baseline to peak severity was 16.4 for trazodone, 18.04 sodium valproate and 18.24 placebo (F = 0.10; NS). Taper success rates were significantly effected by both active agents at the 5-week, but not 12-week, assessment. At 5 weeks post-taper, 79% of sodium valproate and 67% of trazodone, but only 31% of placebo patients were BZ-free (chi(2) = 7.34; df 2; P < 0.03). Major adverse events for trazodone were sedation and dry mouth, and for valproate, diarrhea, nausea and headaches.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 01:58:38